Evidence map›Paper›PMID 40704372›Full record

ArticleDermatology reports2026

Getting even: occurrence of histopathological primitive melanoma diagnoses 3 years after the COVID-19 lockdown.

Francesco Ricci, Gianluca Pistore, Giovanni Di Lella, Luca Fania, Francesca Ricci, Siavash Rahimi, Annarita Panebianco, Cristina Fortes, Damiano Abeni

Abstract read
In one paragraph

Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesco RicciMelanoma Unit, Istituto Dermopatico dell'Immacolata IRCCS, Rome.ORCID 0000-0002-8388-9268
Gianluca PistoreClinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata IRCCS, Rome.ORCID 0009-0004-9423-1607
Giovanni Di LellaSurgical and Oncological Dermatology Unit, Skin Cancer Center, Istituto Dermopatico dell'Immacolata IRCCS, Rome.
Luca FaniaSurgical and Oncological Dermatology Unit, Skin Cancer Center, Istituto Dermopatico dell'Immacolata IRCCS, Rome.ORCID 0000-0003-4194-932X
Francesca RicciIsola Tiberina - Gemelli Isola Hospital, Rome.
Siavash RahimiDepartment of Pathology, Princess Elizabeth Hospital, Saint Martin.
Annarita PanebiancoMedical Direction, Istituto Dermopatico dell'Immacolata IRCCS, Rome.
Cristina FortesClinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata IRCCS, Rome.
Damiano AbeniClinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata IRCCS, Rome.ORCID 0000-0002-0167-7617

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The COVID-19 lockdown in 2020 caused a significant delay in histopathological melanoma diagnoses in Rome, Italy, leading to an increase in Breslow thickness and more aggressive tumor characteristics in the following years. Although there was a partial recovery in the number of diagnoses in 2021 and 2022, melanoma thickness remained higher than pre-pandemic levels. In 2023, our analysis of primary melanoma cases from the Histopathology Registry of Istituto Dermopatico dell'Immacolata IRCCS in Rome showed that Breslow thickness had finally returned to, or even improved beyond, 2019 levels - indicating a resolution of the diagnostic delay. At the same time, the proportion of ulcerated and nodular melanomas declined. These findings underscore the long-term effects of pandemic-related diagnostic disruptions and highlight the importance of maintaining continuous screening programs, even during public health crises. Ongoing public education on melanoma awareness and early detection remains crucial to preventing future delays.

Indexed as

COVID-19epidemiologyMelanoma

Identifiers

PMID40704372
PMCPMC13487731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.